H.C. Wainwright announced it was Reiterated coverage of Onconova Therapeutics Inc. in a research note on March 01, 2018. The analysts assigned a Buy rating to the stock with a price target of $7.50. Maxim Group rated the stock as a Hold in a research noted published on January 17, 2018. H.C. Wainwright rated the stock as a Buy in a research note published on October 09, 2017.
GROOPMAN JEROME, the Director of Onconova Therapeutics Inc., bought 10000.0 shares at the valuation of $0.36 during an exchange that occurred on May 19, which implies that GROOPMAN JEROME is holding 10,001 shares at the estimation of $3,626 dependent on the most recent closing price.
In another transaction, on May 19, SVP Corp Dev & Gen Counsel of Onconova Therapeutics Inc., OLER ABRAHAM N., bought 15000.0 shares at the price of $0.37. After this activity, OLER ABRAHAM N. now keeps 90,000 shares of Onconova Therapeutics Inc., esteemed at $5,550 with the most recent shutting price.
ONTX Recent Trade
The share price of ONTX ascended by $0.13 during the exchanging session on 07/27/20 to exchange at $1.24. Onconova Therapeutics Inc. stock has an exchanging volume of 20.79 million shares, which is high, contrasted with its 3-months average volume of 15.30M shares. Its market capitalization has now reached to $214.82M and analysts have a consensus target price of $1.64 in the 12-month period.
ONTX Past Trading Activity
The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, ONTX price has rose by 13.76%. In the course of past three months sees the stock go up around 309.24%, while it has gain 218.77% over the past six months and 223.76% since the start of the year.
ONTX Earning History
Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Jun 2020), the firm recorded a revenue of 52.0 million, which was higher than the gauge of 170k made by certain experts. For that equivalent quarter, Onconova Therapeutics Inc. posted -$0.03 earnings per share (EPS) which was above the consensus estimate of -$0.05 by $0.02, which represents to an expansion by 40.00%.
ONTX Price Performance
Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Onconova Therapeutics Inc. has seen its stock exchanging -20.51% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +313.33% above its three-month low. A more extensive look sees ONTX exchanging -56.34% beneath its 52-week high and 1107.40% above from its 52-week low price.
ONTX Instability & Beta Factor
The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 18.86%, while it has a month to month instability of 13.00%. The firm has an ATR (Average True Range) of 0.14 and a beta factor of 2.51.